Clinical Trial

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-12; most recent amendment 2026-03-27.
Status change: Not Yet Recruiting → Recruiting 2025-08-26
Trial Details
NCT Number NCT06875960
Lead Sponsor Bristol-Myers Squibb
Conditions Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Enrollment 35 participants
Start Date 2026-02-24
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-30